{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Seftel MD"],"funding":["HRSA/DHHS","National Cancer Institute (NCI)","National Heart, Lung and Blood Institute (NHLBI)","NCI","NHLBI NIH HHS","*Actinium Pharmaceuticals; Allos Therapeutics, Inc.; *Amgen, Inc","NCI NIH HHS","National Cancer Institute (NCI) (to SES)","PHS HHS","Office of Naval Research","the National Institute of Allergy and Infectious Diseases (NIAID)"],"pagination":["322-9"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4764423"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["91(3)"],"pubmed_abstract":["For adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in first complete remission (CR1), allogeneic hematopoietic cell transplantation (HCT) is an established curative strategy. However, pediatric-inspired chemotherapy may also offer durable leukemia-free survival in the absence of HCT. We compared 422 HCT recipients aged 18-50 years with Ph-ALL in CR1 reported to the CIBMTR with an age-matched concurrent cohort of 108 Ph- ALL CR1 patients who received a Dana-Farber Consortium pediatric-inspired non-HCT regimen. At 4 years of follow-up, incidence of relapse after HCT was 24% (95% CI 19-28) versus 23% (95% CI 15-32) for the non-HCT (chemo) cohort (P=0.97). Treatment-related mortality (TRM) was higher in the HCT cohort [HCT 37% (95% CI 31-42) versus chemo "],"journal":["American journal of hematology"],"pubmed_title":["Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission."],"pmcid":["PMC4764423"],"funding_grant_id":["T32 CA009515","P01CA068484 (The DFCI ALL Consortium trials in younger adults)","P30 CA008748","U24-CA076518","Grant/Cooperative Agreement 5U10HL069294","P01 CA068484","N00014-13-1-0039","N00014-14-1-0028","HHSH250201200016C with Health Resources and Services Administration","U10 HL069294","HHSH250201200016C","U24 CA076518","5U10HL069294","Public Health Service Grant/Cooperative Agreement U24-CA076518 (CIBMTR)"],"pubmed_authors":["Wang HL","Sallan SE","Zhang MJ","Bergeron J","Lazarus HM","Seftel MD","Couban S","Freytes CO","Saber W","Tallman MS","Woolfrey AE","Acute Leukemia Committee of the CIBMTR and the Dana Farber ALL Consortium","DeAngelo DJ","Kharfan-Dabaja MA","Soiffer R","Neuberg D","Hamadani M","Paulson K","Nishihori T","Weisdorf DJ","Ballen KK"],"additional_accession":[]},"is_claimable":false,"name":"Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission.","description":"For adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in first complete remission (CR1), allogeneic hematopoietic cell transplantation (HCT) is an established curative strategy. However, pediatric-inspired chemotherapy may also offer durable leukemia-free survival in the absence of HCT. We compared 422 HCT recipients aged 18-50 years with Ph-ALL in CR1 reported to the CIBMTR with an age-matched concurrent cohort of 108 Ph- ALL CR1 patients who received a Dana-Farber Consortium pediatric-inspired non-HCT regimen. At 4 years of follow-up, incidence of relapse after HCT was 24% (95% CI 19-28) versus 23% (95% CI 15-32) for the non-HCT (chemo) cohort (P=0.97). Treatment-related mortality (TRM) was higher in the HCT cohort [HCT 37% (95% CI 31-42) versus chemo ","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Mar","modification":"2025-04-21T18:34:59.047Z","creation":"2019-03-27T02:09:42Z"},"accession":"S-EPMC4764423","cross_references":{"pubmed":["26701142"],"doi":["10.1002/ajh.24285"]}}